Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer

BACKGROUND: Both MET and c-SRC are important mediators of cancer progression and there is cross talk between the two molecules. Preclinical studies have demonstrated combination of MET and c-SRC inhibitors is effective in multiple cancer types. METHODS: We analyzed the safety and efficacy of adminis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Kato, Shumei, Jardim, Denis L., Johnson, Faye M., Subbiah, Vivek, Piha-Paul, Sarina, Tsimberidou, Apostolia M., Falchook, Gerald S., Karp, Daniel, Zinner, Ralph, Wheler, Jennifer, Janku, Filip, Fu, Siqing, Lim, JoAnn, Bean, Stacie, Nguyen, Ly, Urban, Susan, Browne, Elsa, Meric-Bernstam, Funda, Hong, David S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5908757/
https://ncbi.nlm.nih.gov/pubmed/29047029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0513-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados